A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors

Science Translational Medicine

Volumn 5, Issue 187, 2013, Pages

  Toivanen, Roxanne ^a   Frydenberg, Mark ^a   Murphy, Declan ^b   Pedersen, John ^a,c   Ryan, Andrew ^c   Pook, David ^a   Berman, David M ^d   Taylor, Renea A ^a   Risbridger, Gail P ^a  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Tissupath Pty Ltd   (Australia)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CASTRATION TOLERANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR CELL; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; APOPTOSIS; HETEROGRAFTS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84880560009     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005688     Document Type: Article

References (21)

1. C. S. Grasso, Y. M. Wu, D. R. Robinson, X. Cao, S. M. Dhanasekaran, A. P. Khan, M. J. Quist, X. Jing, R. J. Lonigro, J. C. Brenner, I. A. Asangani, B. Ateeq, S. Y. Chun, J. Siddiqui, L. Sam, M. Anstett, R. Mehra, J. R. Prensner, N. Palanisamy, G. A. Ryslik, F. Vandin, B. J. Raphael, L. P. Kunju, D. R. Rhodes, K. J. Pienta, A. M. Chinnaiyan, S. A. Tomlins, The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
2. J. A. Locke, E. S. Guns, A. A. Lubik, H. H. Adomat, S. C. Hendy, C. A. Wood, S. L. Ettinger, M. E. Gleave, C. C. Nelson, Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407-6415 (2008).
3. K. E. Knudsen, T. M. Penning, Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 21, 315-324 (2010).
4. M. J. Pfeiffer, F. P. Smit, J. P. Sedelaar, J. A. Schalken, Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med. 17, 657-664 (2011).
5. H. Beltran, T. M. Beer, M. A. Carducci, J. de Bono, M. Gleave, M. Hussain, W. K. Kelly, F. Saad, C. Sternberg, S. T. Tagawa, I. F. Tannock, New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur. Urol. 60, 279-290 (2011).
6. M. M. Shen, C. Abate-Shen, Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
7. N. Craft, C. Chhor, C. Tran, A. Belldegrun, J. DeKernion, O. N. Witte, J. Said, R. E. Reiter, C. L. Sawyers, Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgendependent tumors through a two-step process. Cancer Res. 59, 5030-5036 (1999).
8. M. Germann, A. Wetterwald, N. Guzmán-Ramirez, G. van der Pluijm, Z. Culig, M. G. Cecchini, E. D. Williams, G. N. Thalmann, Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 30, 1076-1086 (2012).
9. D. R. McCulloch, K. Opeskin, E. W. Thompson, E. D. Williams, BM18: A novel androgendependent human prostate cancer xenograft model derived from a bone metastasis. Prostate 65, 35-43 (2005).
10. R. Toivanen, D. M. Berman, H. Wang, J. Pedersen, M. Frydenberg, A. K. Meeker, S. J. Ellem, G. P. Risbridger, R. A. Taylor, Brief report: A bioassay to identify primary human prostate cancer repopulating cells. Stem Cells 29, 1310-1314 (2011).
11. R. Toivanen, R. A. Taylor, D. W. Pook, S. J. Ellem, G. P. Risbridger, Breaking through a roadblock in prostate cancer research: An update on human model systems. J. Steroid Biochem. Mol. Biol. 131, 122-131 (2012).
12. H. Zhao, R. Nolley, Z. Chen, D. M. Peehl, Tissue slice grafts: An in vivo model of human prostate androgen signaling. Am. J. Pathol. 177, 229-239 (2010).
13. C. Priolo, M. Agostini, N. Vena, A. H. Ligon, M. Fiorentino, E. Shin, A. Farsetti, A. Pontecorvi, E. Sicinska, M. Loda, Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 176, 1901-1913 (2010).
14. D. I. Quinn, The future in advanced prostate cancer: Take your partners or is the last dance for me? Rev. Urol. 6 (Suppl. 10), S29-S44 (2004).
15. X. Wang, M. Kruithof-de Julio, K. D. Economides, D. Walker, H. Yu, M. V. Halili, Y. P. Hu, S. M. Price, C. Abate-Shen, M. M. Shen, A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500 (2009).
16. Y. Sun, J. Niu, J. Huang, Neuroendocrine differentiation in prostate cancer. Am. J. Transl. Res. 1, 148-162 (2009).
17. S. A. Rosenthal, H. M. Sandler, Treatment strategies for high-risk locally advanced prostate cancer. Nat. Rev. Urol. 7, 31-38 (2010).
18. R. A. Taylor, P. A. Cowin, G. R. Cunha, M. Pera, A. O. Trounson, J. Pedersen, G. P. Risbridger, Formation of human prostate tissue from embryonic stem cells. Nat. Methods 3, 179-181 (2006).
19. A. A. Donjacour, G. R. Cunha, Induction of prostatic morphology and secretion in urothelium by seminal vesicle mesenchyme. Development 121, 2199-2207 (1995).
20. G. R. Cunha, A. Donjacour, Mesenchymal-epithelial interactions: Technical considerations. Prog. Clin. Biol. Res. 239, 273-282 (1987).
21. S. J. Ellem, H. Wang, M. Poutanen, G. P. Risbridger, Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic premalignancy. Am. J. Pathol. 175, 1187-1199 (2009).